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Improvements in our understanding of the functions of the nuclear receptor peroxisome proliferator-activated receptor (PPAR)
subtypes as pleiotropic regulators of biological responses, including lipid, lipoprotein, glucose homeostasis, inﬂammation,
diﬀerentiation and proliferation of various cancer cells, and memory, have provided an opportunity to develop novel PPAR
ligands with characteristic subtype selectivity. Such ligands are not only chemical tools to investigate the functions of PPARs,
but also candidates for the treatment of PPAR-mediated diseases, including metabolic syndrome, inﬂammation, dementia, and
cancer. Thisminireview summarizes ourworkonthedesign,synthesis,andpharmacological evaluation ofsubtype-selective PPAR
agonists based on the use of 3,4-disubstituted phenylpropanoic acid as a versatile template.
Copyright © 2008 H. Miyachi and Y. Hashimoto. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. NUCLEAR RECEPTORS
The nuclear receptors (NRs) form a superfamily of ligand-
dependent transcription factors that control diverse aspects
of reproduction, development, homeostasis, immune func-
tion, and so on. This superfamily includes the known
receptors for steroid hormones, thyroid hormones, retinoid
r e c e p t o r sa n dv i t a m i nDr e c e p t o r ,a sw e l la sal a r g en u m b e r
of orphan receptors. The structures of NRs are composed
of several functionally important regions (designated A to
F). The N-terminal A/B region contains a transcriptional
activationfunction-1(AF-1)motifthatworksindependently
of ligand binding. The central DNA-binding region (C
region) is highly conserved among the NRs and contains
two zinc-ﬁnger motifs that make contact with speciﬁc
nucleotide sequences, termed hormone response elements.
The C-terminal part, which consists of the D, E, and
F regions, is required for ligand binding and receptor
dimerization. In most receptors, this region also contains a
second highly conserved transcriptional activation function-
2 (AF-2) motif, which is important for ligand-dependent
transcription.
Based on the elucidated human genome sequence, 48
NRs are speculated to exist in humans [1]. However, the
ligands have been identiﬁed for only 20 to 25 of them. The
others are so-called orphan receptors, whose endogenous
ligands are not known [2, 3]. Among the NRs, much
attention has been focused on the peroxisome proliferator-
activated receptors (PPARs) over the past two decades.
2. PEROXISOME PROLIFERATOR-ACTIVATED
RECEPTORS
PPARs are activated by endogenous saturated and unsatu-
rated fatty acids and their metabolites and synthetic ligands
[4] .T h r e es u b t y p e sh a v eb e e ni s o l a t e dt od a t e :P P A R α
(NR1C1), PPARδ (NR1C2), and PPARγ (NR1C3), and
each of them appears to be diﬀerentially expressed in a
tissue-speciﬁc manner. PPARα is mostly expressed in tissues
involved in lipid oxidation, such as liver, kidney, skeletal,
cardiac muscle, and adrenal glands. PPARγ is expressed in
adipose tissue, macrophages, and vascular smooth muscles.
In contrast to the speciﬁc distribution of PPARα and PPARγ,
PPARδ is ubiquitously expressed [5].2 PPAR Research
Upon ligand binding, PPARs heterodimerize with
another nuclear receptor partner, retinoid X receptor (RXR),
and the heterodimers regulate gene(s) expression by binding
to speciﬁc consensus DNA sequences, called peroxisome
proliferator responsive elements. These elements are a direct
repeat of the hexameric AGGTCA recognition motif, sep-
arated by one nucleotide (DR1), present in the promoter
region of the target genes [6].
3. PPARS AS REGULATORS OF METABOLIC
HOMEOSTASIS
Each of the PPAR subtypes plays a pivotal role in lipid,
lipoprotein, and glucose homeostasis. PPARα regulates genes
involved in fatty acid uptake (such as fatty acid binding
protein, FABP), β-oxidation (acyl-CoA oxidase), and ω-
oxidation (cytochrome P450). It downregulates apolipopro-
tein C-III, a protein that inhibits triglyceride hydrolysis by
lipoprotein lipase, and it also regulates genes involved in
reverse cholesterol transport, such as apolipoprotein A-I
and apolipoprotein A-II [7]. PPARγ is a master regulator
of adipocyte diﬀerentiation, but more recent molecular-
biological studies have indicated that its activation is also
linked to the expression of many important genes that aﬀect
energy metabolism, such as TNF-α, leptin, and adiponectin
genes [8]. PPARδ is the least well-deﬁned subtype among
the PPARs, but recent biological study has disclosed that
its activation signiﬁcantly increases HDL cholesterol levels,
and it inﬂuences glycemic control in a primate model
of metabolic syndrome [9–11]. Furthermore, its activation
markedly improved glucose tolerance and insulin resistance
in ob/ob mice, although the underlying mechanism remains
unclear [12].
4. PPARS AS TEMPLATES FOR DEVELOPMENT OF
VERSATILE REGULATORS
Research in the ﬁeld of PPAR biology and/or pharmacology
is attracting enormous interest, and the range of therapeutic
potential for PPAR agonists is rapidly expanding well beyond
lipid, lipoprotein, and glucose homeostasis. For example,
ligand-mediated PPARα activation induces expression and
activation of antioxidant enzymes, such as superoxide
dismutase (SOD) and glutathione peroxidase (GTP) [13].
Therefore, PPARα activation blocks the synthesis and release
of inﬂammatory cytokines, such as IL-6 and TNF-α.P P A R γ
activation attenuates the expression of inducible nitric oxide
(iNOS) and cyclooxygenase-2 (COX-2), as well as the
production of proinﬂammatory cytokines [14]. Considering
that PPARs are also expressed in neurons and in astrocytes,
both PPARα and PPARγ are expected to be useful as
pharmacological targets for neuroprotection in stroke and
neurodegenerative diseases.
PPARγ was initially noted to be highly expressed in
adipose tissue, but later studies demonstrated that PPARγ
was also expressed widely in tumors originated from various
organs. Ligand-mediated activation of PPARγ inhibits cell
proliferation and/or induces apoptosis or terminal diﬀeren-
tiation, by upregulating the expression of cyclin-dependent
kinase (CDK) inhibitors, including P18, P21, and P27 [15].
PPARγ also promotes cell cycle arrest by inhibiting CDK
activity in several tumor cell lines [16].
Angiogenesis, the formation of new blood vessels, is a
criticalstepinsolidtumorgrowth.PPARγ activationinhibits
the expression of at least three important genes involved in
the angiogenic processes, that is, VEGF, VEGF receptor 1,
and urokinase plasminogen activator (uPA) [17]. Therefore,
PPARγ is considered as a therapeutic target for certain
human malignancies.
Basedontheﬁndingsthattheglitazone-classantidiabetic
agents and ﬁbrate-class antidyslipidemic agents are ligands
of PPARγ and PPARα, respectively, much research interest
has been focused on these two metabolic NR subtypes
as therapeutic targets for the treatment of diabetes and
dyslipidemia. In contrast, although PPARδ is ubiquitously
distributed in a wide range of tissues and cells, research
interest in PPARδ has been limited. However, after 2001, the
availability of PPAR δ knockout animals and selective ligands
prompted us to examine the involvement of PPARδ in fatty
acidmetabolism,insulinresistance,reversecholesteroltrans-
port, inﬂammation, and so on. Furthermore, molecular-
pharmacological studies have indicated that PPARδ is also
involved in other biological functions, extending beyond
metabolic homeostasis. PPARδ is reported to play critical
role(s) in wound healing. After tissue damage resulting from
chemical, mechanical, and biological injury, the injured cells
release proinﬂammatory cytokines [18, 19]. These stimulate
PPARδ expression, coordinating transcriptional upregu-
lation of integrin-linked kinase and 3-phosphoinositide-
dependent kinase (PDK), and repress the expression of
phosphatase and tensin homolog 10 (PTEN) [20]. As a
consequence, the PKBα activity is increased and apoptotic
cascades are repressed. The resulting increased resistance to
cell death helps to maintain a suﬃcient number of viable
woundkeratinocytes forre-epithelization. Therefore,PPARδ
is expected to be a therapeutic target for tissue injury.
The above examples remind us that PPARs are
pleiotropic NRs, and the subtypes are unique, though
somewhat overlapping, therapeutic targets for the treatment
of not only metabolic homeostasis, but also inﬂammation,
cancer, neurodegeneration, wounds, and so forth. PPAR
ligands clearly have enormous potential as therapeutic
agents, and the range of possible applications has certainly
not yet been fully explored.
From a basic research point of view, it is of primary
importance to develop potent and PPAR subtype-selective
ligands as chemical tools to investigate individual PPAR
functions in detail. Furthermore, from a medicinal chemical
point of view, it is also important to consider PPAR dual
agonists (which can activate two out of three PPAR subtypes
eﬀectively), such as PPARα/δ-, PPARα/γ-, and PPARδ/γ dual
agonists,andPPAR-panagonists(whichcanactivateallthree
PPAR subtypes), since these may exhibit additive and/or
synergistic pharmacological eﬀects.
In this minireview, we focus on our structural devel-
opment studies to create PPARα-selective PPARα/δ-dual
and PPARδ-selective agonists, using the 3,4-disubstituted
phenylpropanoic acid template as a common structure.H. Miyachi and Y. Hashimoto 3
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Figure 1: Structures of: (1) PPARγ agonist pioglitazone, (2) PPARα agonist fenoﬁbrate, (3) PPARδ agonist GW-501516, and (4) dual
PPARγ/α agonist KRP-297.
5. OUR WORKING HYPOTHESIS CONCERNING
THE LIGAND SUPERFAMILY CONCEPT
We have been engaged in structural development studies
of NR ligands (agonists and antagonists) for over ten
years, based on our working hypothesis concerning the
NR ligand superfamily concept [21]. Broadly speaking,
the structural/functional features of NRs are similar, even
though there are many kinds of NRs (48 in humans), that
is, NRs generally consist of an aminoterminal region which
has a ligand-independent transcriptional activation func-
tion (AF-1), a DNA-binding domain (DBD) with a motif
structure of two zinc ﬁngers which has a sequence-speciﬁc
DNA (response element: RE)-binding function, and a large
carboxyl-terminal region (ligand-binding domain: LBD),
which has a speciﬁc ligand-binding function/dimerization
function/ligand-dependent activation function (AF-2) [22].
Thus, NRs are probably derived from a single ancestral
protein, and may have structurally evolved in order to ﬁt
various kinds of endogenous NR ligands. We speculated that
similar evolution of NR ligands would have occurred from
an ancestral ligand to form a superfamily, even though NR
ligands now have diverse functions. Based on this working
hypothesis, we divided the structure of NR ligands into two
portions. One is a common hydrophobic framework that ﬁts
into the ligand binding pocket of the basic ancestral protein,
and the other is a characteristic structural motif which
providesNRselectivity.Ifthishypothesisiscorrect,itiseasily
deduced that the hydrophobic backbones of various NR
ligands should be exchangeable with each other to construct
structurally new NR ligands.
Numerous previous reports have indicated that PPAR
subtype-selective agonists have certain unique structures
associated with the subtype selectivity. For example,
thiazolidine-2,4-dione, and related structures, as exempliﬁed
by pioglitazone (1), for PPARγ selective agonists, 2,2-dialkyl
(usually dimethyl) phenoxyacetic acid structure, exempliﬁed
by fenoﬁbrate (2), for PPARα-selective agonists, and 2,2-
unsubstituted phenoxyacetic acid structure, exempliﬁed by
GW-501516 (3), for PPARδ-selective agonist (Figure 1). But,
basedonourworkinghypothesis,weanticipatedthatvarious
kinds of subtype-selective, dual-, and pan-agonists could
be created by using a common chemical framework as a
template.
6. PPARα-SELECTIVE AGONIST: KCL
We designed and synthesized a series of substituted phenyl-
propanoic acid derivatives in order to develop structurally
new human PPARα-selective agonists, using KRP-297 (4), a
unique thiazolidine-2,4-dione derivative with PPARγ/α dual
agonist activity, as a lead compound for the preparation of
antidyslipidemic agents [23–25]. Although KRP-297 belongs
structurally to the glitazones (thiazolidine-2,4-dione class
insulin sensitizers), it binds directly to and activates not
only PPARγ, but also PPARα with almost equal aﬃnity (its
aﬃnity for PPARγ and PPARα is approximately 0.23 and
0.33μM, resp., and it transactivates PPARγ and PPARα with
eﬀective concentrations of 0.8 and 1.0μM, resp.) [24]. This
is a characteristic feature of classical glitazones, including
troglitazone (5), pioglitazone (1), and rosiglitazone (6),
which were reported to bind to and activate selectively
the PPARγ subtype. The reason why they exhibit dual-
ligand nature was unclear, but we anticipated that the
replacement of the thiazolidine-2,4-dione ring structure
of KRP-297 with another acidic functionality, such as a
carboxyl group, which is usually used in ﬁbrates, might
favor PPARα selectivity and that further chemical mod-
iﬁcation might improve the potency and selectivity for
the PPARα subtype. Structurally, KRP-297 can be regarded
as having three key regions: (i) the acidic head group,
(ii) the linking group, and (iii) the hydrophobic tail
group. We performed chemical modiﬁcation of the (i) to
(ii) parts of the molecule to understand the structure-
activity relationship in detail. After synthesizing numer-
ous compounds, we obtained KCL, (S)-2-[4-methoxy-3-(4-
triﬂuoromethylbenzylcarbamoyl)phenylmethyl]butyric acid
(S)-11 [26–29]a sap o t e n ta n dP P A R α-selective agonist.
The synthetic route to KCL is shown in Scheme 1.O u r
SAR results can be summarized as follows. (i) The distance
between the carboxyl group and the right-side benzene
ring in the compound is important. (ii) The introduction
of alkyl substituents at the α-position of the carboxyl
group strikingly aﬀected PPARα transactivation activity
and subtype selectivity, and the ethyl group is the most
favorable (Table 1). (iii) Stereochemistry at the α-position
of the ethyl group is crucial and the (S)-conﬁguration
is preferable (Figure 2). (iv) The length of the linking
group is important for potency, and a three-atom unit4 PPAR Research
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Scheme 1: Chemical structure of our PPARα-selective agonist KCL, and the synthetic route. Reagents and conditions: (a) BnBr, KHCO3,
DMF, rt., (b) MeI, K2CO3,D M F ,r t .( c )N a B H 4,E t O H ,r t .( d )P B r 3,e t h e r ,0 ◦C, (e) (1) (R)-4-benzyl-3-butyryloxazolidin-2-one, LiHMDS,
THF, −40◦C–−10◦C, (2) benzyl 5-bromomethyl-2-methoxybenzoate, THF, −40◦C–−10◦C, (f) H2,1 0 %P d – C ,A c O E t ,r t . ,( g )( 1 )e t h y l
chloroformate, TEA, THF, −10◦C, (2) 4-triﬂuoromethylbenzylamine, THF, −10◦C -rt., (h) LiOH H2O, H2O2, THF–H2O, 0◦C.
with an amide group such as –CH2–NH–CO– is preferable
(Table 2).
(Although compound 29 exhibited potent and PPARα-
selective activity, we did not go forward with this compound,
because our experience indicated that it would be metabol-
ically unstable; consequently it was not expected to exhibit
potent or prolonged in vivo activity, despite its potency in
vitro.)
It is important to note that KCL exhibits distinct species-
dependence in transactivation for PPARα. Although species
dependency of some PPARα agonists was reported previ-
ously, the degree of selectivity was low [30, 31]. However, the
species-selectivity of KCL is extremely high: KCL activated
human, dog, and rat PPARα with EC50 values of 0.06, 0.16,
and 5.2μM, respectively (Table 3). KCL exhibited species
preference for humans and its transactivation activity for
PPARα was approximately 100-fold and 30-fold less potent
in rats than in humans and in dogs, respectively.
This apparent species diﬀerence was reported to result
from speciﬁc interaction between the 272-aminoacid,
isoleucine (Ile272), which is located on the helix 3 region
of the human PPARα LBD and the hydrophobic tail part
of KCL [32–34]. The corresponding aminoacid residue in
the rat PPARα LBD is sterically more bulky phenylalanine.
KCL was reported to reduce plasma triglyceride levels >100-
fold more potently in dogs than in rats, which is consistent
with the in vitro assay data. Clinical studies of a KCL-related
compound are under way.
7. PPARα/δ-DUAL AGONIST: TIPP-401
We next planned to develop a PPARα/δ-dual agonist, which
would eﬀectively activate both PPARα and PPARδ,b e c a u s e
pharmacological evidence indicated that PPARα regulates
the expression of genes encoding proteins involved in lipid
and lipoprotein homeostasis, and subsequent pharmacolog-
ical ﬁndings for PPARδ demonstrated that it also plays a keyH. Miyachi and Y. Hashimoto 5
Table 1: SAR 1: eﬀect of the acidic partial structure in the present series of compounds.
F
F F
O
N
H
R
MeO
Transactivation activity
EC50 (nM)(a)
No. R PPARα PPARδ PPARγ
7C O O H i a (b) ia ia
8C H 2COOH ia ia ia
9( C H 2)2COOH 1300 ia ia
10 CH2CH(Me)COOH(c) 240 2800 ia
11 CH2CH(Et)COOH(c) 40 3600 1000
12 CH2CH(n-Pr)COOH(c) 360 2400 ia
13 CH2CH(i-Pr)COOH(c) 290 ia ia
14 CH2CH(n-Bu)COOH(c) 1000 ia 2500
15 CH2CH(Ph)COOH(c) ia ia ia
16 CH2CH(OMe)COOH(c) 230 ia ia
17 CH2CH(OEt)COOH(c) 1600 3000 2800
18 CH2CH(OPh)COOH(c) ia ia ia
19 CH2C(Me)2COOH 2900 ia ia
20 CH2C(Et)2COOH 2800 ia ia
21 CH2CH(SEt)COOH(c) 1600 3000 2800
22 CH2CH(SPh)COOH(c) ia ia ia
23 CH2CH(SBn)COOH(c) ia ia ia
KRP-297 1000 ia 800
(a)Compounds were screened for agonist activity on PPAR-GAL4 chimeric receptors in transiently transfected CHO-K1 cells as described. EC50 value is the
molar concentration of the test compound that causes 50% of the maximal reporter activity,
(b)“ia” means inactive at the concentration of 10μM,
(c)assayed as a racemate.
Table 2: SAR 2: eﬀect of the linker partial structure in the present series of compounds.
F
F
F
A
OH
O
MeO
Transactivation activity
EC50 (nM)(a)
No. A PPARα PPARδ PPARγ
11 CH2NHCO(c) 40 3600 1000
24 NHCO(c) 6000 ia(b) ia
25 (CH2)2NHCO(c) 740 1500 ia
26 CH2N(Me)CO(c) ia ia ia
27 CH2CONH(c) 130 ia ia
28 NHCONH(c) ia ia ia
29 NHCOCH2
(c) 20 ia ia
30 CH2CH2CO(c) 320 ia 7400
31 CH2CH2CH2
(c) 860 640 ia
32 CH2CH2O(c) 680 400 ia
33 CONHCH2
(c) 40 120 10000
34 CH2NHCH2
(c) 4900 8000 ia
(a),(b),(c)See footnotes of Table 1.6 PPAR Research
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Figure 2: Dose-response curves of each enantiomer for PPARα
transactivation.
Table 3: Species diﬀerences in the transactivation of PPARα
isoforms.
Transactivation activity
EC50 (nM)(a)
Compd. Human Dog Rat
KCL 60 160 5200
fenoﬁbrate 41000 50000 49000
(a)S e ef o o t n o t eo fTable 1.
roleinlipid metabolismandinsulinresistance.Furthermore,
PPARδ plays a key role in foam cell and macrophage
activation in atherosclerosis.
The metabolic function(s) of PPARδ seem to be mainly
targeted to adipose tissue and smooth muscle, via fatty acid
oxidation and energy uncoupling. If this were the case, we
expectedthatacompoundwhichcaneﬀectivelyactivateboth
PPARα and PPARδ might have additive and/or synergistic
positive eﬀect(s) in the treatment of metabolic syndrome,
by modulating both hepatic fatty acid oxidation through
PPARα, and fatty acid oxidation and energy uncoupling
in muscle and adipose tissue through PPARδ. In addition,
in 2004, there were only a few examples of PPARα/δ dual
agonists in the literature, including compounds 35 [35], 36
[36], and 37 [37]( Figure 3), and their activities seemed
rather low and their structural variety poor. Therefore, there
was considerable interest in creating novel PPARα/δ dual
agonistsfrombothbasicscientiﬁcandclinicalpointsofview.
We expected that small manipulations of the structure of
KCL would aﬀect the activities towards both PPARα and
PPARδ. Therefore, we reconsidered the SAR of PPARα-
selective KCL derivatives.
As the linking group of the KCL series, we found
that a three-atom unit with an amide group such as
−CH2−NH−CO− was preferable for potency and selectivity
against PPARα, and these compounds did not exhibit
remarkable PPARδ activity. We noted that a ﬂexible linker,
such as −CH2−CH2−CH2− (31) or −CH2−CH2−O−
(32), decreased PPARα transactivation activity, but also
resulted in the appearance of PPARδ transactivation activity.
Therefore, we focused our attention on a hybrid-type
linker, that is, −CO−NH−CH2− (33), and found that this
linker increased both PPARα and PPARδ transactivation
activity to some extent, as compared with the amide-type
(−CH2−NH−CO−) linker in KCL (Table 2).
We selected 33 as the next lead compound, and
performed further chemical modiﬁcations, focusing
especially on the hydrophobic tail part of the molecule, and
obtained a PPARα/δ-dual agonist termed TIPP-401 ((S)-
2-{3-[(2-ﬂuoro-4-triﬂuoromethylbenzoylamino)methyl]-
4-methoxybenzyl}butyric acid). The synthetic route is
summarized in Scheme 2. We found that the introduction
o faﬂ u o r i n ea t o ma ﬀected the PPAR transactivation activity
or selectivity (Table 4). Compounds 38 and 39, which have
a ﬂuorine atom at the ortho-o rmeta-position of benzene
in the hydrophobic tail part, respectively, exhibited more
potent PPARα and PPARδ transactivation activities than
those of the nonﬂuorinated compound. The position of
the distal benzene substituents is crucial, since compound
40, which has a ﬂuorine atom at the para-position and
a triﬂuoromethyl group at the meta-position, showed
considerably decreased PPAR transactivation activity. This
is consistent with the previously obtained SAR result that
steric bulkiness at the para-position is an important factor
for potent PPARα transactivation activity.
Considering these results, we prepared optically active
derivatives, 41 (TIPP-401), 42, and 43. As can be seen
from Table 4, a clear enantio-dependency of the trans-
activation activity towards the PPARα and PPARδ iso-
forms was found. Compound 42, which has (S)c o n ﬁ g -
uration, exhibited potent transactivation activity towards
both PPARα and PPARδ, while the antipodal (R) isomer
43 exhibited far less potency. Therefore, we concluded that
both PPARα and PPARδ transactivation activities reside
almost exclusively in the (S)-enantiomer, and both TIPP-
401 and 42 show dual-agonist activity toward PPARα and
PPARδ. The synthetic route to TIPP-401 is shown in
Scheme 2.
I no r d e rt oi n v e s t i g a t et h en u c l e a rr e c e p t o rs e l e c t i v i t y
(cross-reactivity) of the representative compound TIPP-401,
we determined the transactivation activity of TIPP-401 on
representative nuclear receptors (PPARs, VDR, FXR, LXRα,
RARα,a n dR X R α). As can be seen from Figure 4,T I P P -
401 seems to be speciﬁc for PPARα and PPARδ because it
did not signiﬁcantly activate VDR, PPARγ,L X R α,R A R α,o r
RXRα at concentrations up to 1μM under the experimental
conditions used. These results indicate that although the
ligand binding domains of nuclear receptors are similar,H. Miyachi and Y. Hashimoto 7
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there are distinct structural requirements for preferential
binding to both PPARα and PPARδ.
8. PPARδ-SELECTIVE AGONIST: TIPP-204
Our next target was a PPARδ-selective agonist. As described
above, the availability of PPAR δ knockout animals and
selective ligands, especially GW-50151 (3), developed by
GlaxoSmithKline, prompted to examine the involvement
of PPARδ in fatty acid metabolism, insulin resistance,
reverse cholesterol transport, inﬂammation, and so on. For
example, ligand-mediated PPARδ activation signiﬁcantly
increased HDL cholesterol levels, possibly in association
with decreased lipoprotein lipase activity, in insulin-resistant
middle-aged obese rhesus monkeys [38]. In a primate
modelofthemetabolicsyndrome,PPARδ activationlowered
plasma insulin levels, without any adverse eﬀect on glycemic
control [38]. Similarly, in the case of ob/ob mice, PPARδ8 PPAR Research
Table 4: In vitro functional PPAR transactivation activity of substituted phenylpropanoic acids.
Y
O
OH
O
N
H
MeO
X
Transactivation activity
EC50 (nM)(a)
No. X Y stereo PPARα PPARδ PPARγ
33 4-CF3 H rac 19 200 2600
38 4-CF3 2-F rac 10 24 2200
39 4-CF3 3-F rac 11 51 6000
40 3-F 4-CF3 rac 250 2000 ia(b)
41 4-CF3 2-F S 10 12 1900
42 4-CF3 3-F S 12 23 4900
43 4-CF3 3-F R 150 840 ia(b)
(a)Compounds were screened for agonist activity on PPAR-GAL4 chimeric receptors in transiently transfected HEK-293 cells. The EC50 value is the molar
concentration of the test compound that causes 50% of the maximal reporter activity,
(b)“ia” means inactive at the concentration of 10μM.
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Figure 4: Cross-nuclear receptor reactivity of 0.1μM, and 1μM
TIPP-401.
activation markedly improved glucose tolerance and insulin
resistance [38]. All these observations suggest that PPARδ
may be an eﬀective target for the treatment of metabolic
syndrome.
Several PPAR δ selective agonists (44–48) have been
reported in the literature (Figure 5) after the disclosure
of GW-501516 (3), though most are derivatives of GW-
501516 (3) and L-165041 (44) (Merck’s compound), that
is, (2-methyl)phenoxyacetic acid derivatives [39–44]. As
a part of our continuing research directed toward the
structural development of characteristic subtype-selective
PPAR agonists, we planned to construct phenylpropanoic
acid-type PPAR δ selective agonists, based on the PPARα/δ
dual agonist, TIPP-401 as a lead compound.
To create PPARδ-selective agonists, we took into account
the results of X-ray crystallographic analyses of PPARδ
complexed with a natural unsaturated fatty acid, eicosapen-
taenoic acid (EPA) [45]. The PPAR ligand-binding pocket
forms a large Y-shaped cavity which extends from the C-
terminal helix to the β-sheet lying between helix 3 and helix
6. EPA binds to the cavity in two distinct conformations,
that is, tail-up and tail-down conformations. The carboxyl
group and the ﬁrst eight carbon units take almost the
same conﬁguration in both conformations. However, the
distal hydrophobic tail part of the tail-up conformer of EPA
was bent upwards into the upper cavity of the Y-shaped
pocket, while in the tail-down conformer, the hydrophobic
tail part was bent downwards into the bottom cavity of the
Y-shaped pocket. Contrary to the case of PPARδ,n o n eo f
the PPARα and PPARγ agonists whose binding structures
have been solved by X-ray crystallography takes the tail-up
conformation, although the reason for this is not known.
However, we speculated that the aminoacid(s) forming the
entrance to the upper cavity might be bulkier in PPARα
and PPARγ than in PPARδ. We previously suggested that
our PPARα-selective agonist KCL might take a tail-down
conformation, based on molecular modeling studies of
the KCL-PPARα complex and the results of site-directed
mutagenesis studies of PPARα with our PPAR agonists. The
PPARα/δ dual agonist TIPP-401 was also considered to dock
into the downward cavity of PPARα, because Ile272, which is
located on the lower half of helix 3, is also critical for potent
PPARα transactivation by TIPP-401.
Based on these insights, we hypothesized that if we
could connect one more sterically bulky hydrophobic
side chain to the backbone of TIPP-401, directed towards
the upper cavity of PPARδ, it should have the eﬀect of
strengthening the PPARδ activity, while weakening the
PPARα activity. Based on our previously reported binding
model of KCL, a methoxy group at the 4-position was
expected to be directed towards the upper cavity, so we
prepared various 3-(4-alkoxyphenyl)propanoic acids, and
found the compound termed TIPP-204 ((S)-2-{3-[(2-
ﬂuoro-4-triﬂuoromethylbenzoylamino)methyl]-4-buthoxy-
benzyl}butyric acid). The structure and the method ofH. Miyachi and Y. Hashimoto 9
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Figure 5: Structures of representative, recently reported PPARδ-selectiv agonists.
preparation are summarized in Scheme 3. We obtained clear
SAR conﬁrming that the subtype-selectivity largely depends
on the nature of the substituents, as expected.
That is, as regards PPARα, introduction of a short-
chain alkoxy group was found to be favorable for the
transactivation activity, that is, the ethoxy (50) and methoxy
(49) derivatives exhibited the most potent activity. In
contrast, a longer alkoxy group was preferable in the case of
PPARδ transactivation activity, and the n-butoxy (52) and
n-propoxy (51) derivatives were the most potent (Table 5).
These results are consistent with the working hypothesis
that the shape and the environment of the hydrophobic
cavity hosting the alkoxy group at the para-position diﬀer
somewhat among these PPAR subtypes. These compounds
were basically weak agonists for the PPARγ subtype, because
eachcompoundexhibitedanEC50 valueofmicromolarorder
or less.
As described above, the introduction of a ﬂuorine atom
on the distal benzene ring, especially at the 2-position, was
found to enhance the PPAR transactivation activity, as in
TIPP-401. Therefore, we prepared ﬂuorinated compounds
55–57. As expected, these compounds exhibited enhanced
PPARα and PPARδ transactivation activities as compared
with the nonﬂuorinated compounds. We found that the
PPARδ transactivation activity of 57 is comparable with
that of GW-501516 in our assay system, and the selectivity
indexes for PPARδ over both PPARα and PPARγ are more
than 100-fold (Table 5).
As mentioned above, the substituent at the α-position of
the carboxyl group is also important for the potency in the
case of PPARα, and therefore we investigated the eﬀect of
substitution at this position in the present series. As regards
PPARα, introduction of an ethyl group (49) or a methyl
group (59) was favorable for the transactivation activity, and
further elongation of the substituent decreased the activity.
Similarly, an ethyl group (49) or an n-propyl group (60)
was favorable for PPARδ transactivation activity, and further
elongation of the substituent decreased the activity (Table 5).
These results may mean that the shape and the environment
of the cavity hosting the alkyl group located at the α-
position of the carboxyl group are similar in PPARα and
PPARδ.
Considering these results, we then prepared the opti-
cally active derivatives 65 (S-isomer)(TIPP-204) and 66
(R-isomer). As expected, clear enantio-dependency of the
transactivation activity towards the PPAR subtypes was
found,andTIPP-204,whichhas(S)-conﬁguration,exhibited
more potent transactivation activity than the antipodal
(R)-isomer, 66 (Table 5). Therefore, we concluded that the
activity also resides primarily in the (S)-enantiomer, but
the degree of the enantio-selectivity is less apparent than in
the case of the PPARα/δ dual agonist, TIPP-401. TIPP-204
exhibited extremely potent PPARδ transactivation activity,
comparable with or even superior to that of the known
PPARδ-selective agonist GW-501516, and its PPAR subtype
selectivity was also high (Figure 6).10 PPAR Research
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To investigate the nuclear receptor selectivity (cross-
reactivity) of TIPP-204, we analyzed the transactivation
activity of TIPP-204 on representative nuclear receptors
(PPARs, VDR, FXR, LXRα,R A R α,a n dR X R α) in the same
w a ya sw i t hT I P P - 4 0 1( Figure 7). TIPP-204 seems to be
speciﬁc for PPARδ (and to a lesser extent PPARα)b e c a u s e
it did not signiﬁcantly activate VDR, PPARγ,L X R α,R A R α,
or RXRα at concentrations up to 300nM (more than 300-
fold higher concentration as compared to the EC50 of
TIPP-204) under the experimental conditions used. These
results indicate that, although the ligand-binding domains
of nuclear receptors are similar, there are distinct structural
requirements for preferential binding of TIPP-204 to PPARδ.
We have successfully obtained a potent and selective,
structurally novel PPARδ agonist, TIPP-204. In order to
investigate the structure-activity relationship, and the rea-
son for the PPARδ selectivity, we analyzed the three-
dimensional structure-activity relationship by means of the
comparative molecular ﬁeld analysis (CoMFA) method, and
a molecular modeling study (Figures 8–10). (Comparative
molecular ﬁeld analysis (CoMFA) was used to construct
a three-dimensional quantitative structure-activity relation-
ships model. The atomic charges of each conformer were
calculated using the semiempirical method MNDO with
electrostatic potential-derived point charges (MNDO/ESP)
in MOPAC2002. Conventional CoMFA was performed using
the QSAR option implemented in the SYBYL package.
CoMFA ﬁelds were derived in a 3D cubic lattice with a
grid spacing of 2 ˚ A and extending 4 ˚ A beyond the aligned
molecules in all directions. CoMFA steric (Lennard-Jones
6-12 potential) ﬁeld energies and CoMFA electrostatic
(Coulombic potential) ﬁelds were calculated using a probe
atom with the van der Waals properties of sp3 carbon and
a charge of +1.0. CoMFA electrostatic ﬁelds were calculatedH. Miyachi and Y. Hashimoto 11
Table 5: PPARs transactivation activity of the present series of compounds.
F
F
F
N
H
O
O
OH
O R1
R2
R3
Transactivation activity
EC50 (nM)(a)
No. R1 R2 R3 stereo PPARα PPARδ PPARγ
49 H Me Et rac 18 170 2600
50 H Et Et rac 12 15 1800
51 H n-Pr Et rac 77 6.8 1300
52 H n-Bu Et rac 520 4.8 1300
53 H n-Hexyl Et rac 1200 45 2300
54 H Bn Et rac >10000 110 6200
55 F Me Et rac 8.2 21 2200
56 F n-Pr Et rac 41 1.7 650
57 F n-BU Et rac 280 1.9 1400
58 H Me H rac 210 3000 >10000
59 H Me Me rac 19 210 >10000
60 H Me n Pr rac 70 120 3600
61 H Me n BU rac 230 700 2400
62 F Me n Pr rac 29 40 1500
63 F Me n BU rac 140 220 1000
64 F n-BU n Pr rac 820 5.1 1000
65 F n-BU Et S 250 0.91 1100
66 F n-BU Et R 620 8.2 7600
GW-501516 1000 1.8 8600
(a) Compounds were screened for agonist activity on PPAR-GAL4 chimeric receptors in transiently transfected HEK-293 cells. The EC50 value is the molar
concentration of the test compound that causes 50% of the maximal reporter activity.
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Figure 6: Dose-dependency of TIPP-204 for transactivation of
PPARs.
with a distance-dependent dielectric at each lattice point.
TheSYBYLenergycutoﬀof30kcal/molwasused.InCoMFA
calculation, potential functions (a Lennard-Jones potential
and a Coulombic potential) are very steep near the van der
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Figure7:Nuclearreceptorselectivity(crossreactivity)ofTIPP-204.
Waals surface, causing rapid change, so that the use of cut-
oﬀ values is required. The poses of ligands generated from
theGlideprogramwereusedtocarryoutpartial-least-square
(PLS) regression analyses. The CoMFA ﬁelds were used as12 PPAR Research
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Figure 9: Comparison of the CoMFA counterplot of the steric ﬁeld based on TIPP-401 (right) and the superimposition of TIPP-401 on the
ligand-binding domain of PPARδ (left). The CoMFA steric counter map is shown in green and yellow. Green: areas in which bulky atomic
groups are sterically favorable for the activity. Yellow: areas in which bulky atomic groups are unfavorable for the activity.
independent variables and the logarithm of the reciprocal of
EC50 was used as the dependent variable in PLS regression
analyses. The optimal number of components in the PLS
model was determined using the cross-validated coeﬃcient
r2 (called q2) values obtained from the leave-one-out cross-
validation technique. The PLS model with the highest q2
values was then selected to derive 3D QSAR models and
the poses of ligands with respect to the PPARδ LBD.)
Comparison of the CoMFA counterplots with the crystal
structure of the PPARδ ligand-binding domain provided
information about how structural changes of the agonists
aﬀect their activities. As can be seen in Figure 8,h y d r o g e n -
bonding interaction was observed between carbonyl oxygen
of the reversed-amide type linker and threonine 288 (T288)
of PPARδ (Figure 8 left panel), while such a hydrogen-
bonding interaction was not found between carbonyl oxygen
of the amide-type linker and T288 (Figure 8 right panel).
This might be one of the reasons why the change of the
linker from amide type to reversed-amide type enhanced the
PPARδ transactivation activity by 10-fold.
In this CoMFA model (Figure 9), the introduction of
a sterically bulky group near the methoxy group at the 4-
position in the present series favors the activity, and this
was deduced to be related to the presence of the upper
cavity in the Y-shaped ligand-binding domain of PPARδ.
Based on our molecular modeling (Figure 10), we speculated
that the side-chain butoxy group of TIPP-204 ﬁts into
the upper cavity of hPPARδ formed by the hydrophobic
aminoacids V334, L339, and I364. In the case of hPPARα,
the corresponding cavity is composed of sterically bulkierH. Miyachi and Y. Hashimoto 13
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Figure 11: SAR summary of the present series of compounds.
aminoacids, M325, M330, and M355. Indeed, the volume
of the hPPARα upper cavity was calculated to be only one
third of that of the hPPARδ upper cavity, and we considered
that it might not readily accommodate the bulky butoxy
group of TIPP-204. In order to conﬁrm this idea, an X-
ray crystallographic analysis in combination with molecular
modeling is in progress.
9. CONCLUDINGREMARKSANDFUTUREDIRECTIONS
In this minireview, we have described our PPAR ligands
based on 3,4-disubstituted phenylpropanoic acid structure
as a versatile template for subtype-selective PPARs ligands,
basedonourligandsuperfamilyworkinghypothesis.Wealso
describe their pharmacological evaluation. We succeeded in
obtaining three kinds of subtype-selective PPARs ligands,
that is, the PPARα selective agonist KCL, the PPARα/δ-dual
agonist TIPP-401, and the PPARδ selective agonist TIPP-
204. The structure-activity relationships among ligands
for PPARα and PPARδ were well charcterized, and are
summarized in Figure 10.
Basically, our series of compounds showed weak activity
against the PPARγ subtype. However, considering the mod-
erately high-sequence similarity among PPARs, it should be
possible to obtain greater activity. So, we are conducting fur-
ther chemical modiﬁcation studies directed towards PPARγ
activity. Some novel structural requirements for PPARγ
activityhavealreadybeenidentiﬁed.Weexpecttoreport3,4-
disubstituted phenylpropanoic acid-type PPAR-pan agonists
in the near future.14 PPAR Research
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